Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baker Medical Research Institute, Australia
TREAT is expected to help find optimal approach to anemia management in diabetes
July 4th, 2006
Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alpha) Therapy (TREAT) is expected to find the optimal approach to the management of anemia in diabetes. "Anemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment. In tertiary clinics, at least one outpatient in five with diabetes has anemia, for whom it constitutes a significant additional burden," scientists writing in the journal Diabetologia report in their discussion. M.C. Thomas and colleagues at Baker Medical Research Institute explained, "Anemia is associated with an increased risk of diabetic complications...
Source: Pharma Law Weekly (2006-07-04)
|
